checkAd

    DBV Technologies  711  0 Kommentare IND Acceptance from FDA for a proof-of-concept trial using Viaskin® Milk in Milk-Induced Eosinophilic Esophagitis in Children - Seite 3

    DBV Technologies Contacts
    Nathalie Donne
     Director, Corporate Communication & Business Development
     Tél. : +33(0)1 55 42 78 72
    nathalie.donne@dbv-technologies.com     		Susanna Mesa
    VP Finance, US Investor Relations & Strategy
    Tél. : +1 917-346-3447
    susanna.mesa@dbv-technologies.com
    DBV Technologies Media Contacts US & Europe 
    Marion Janic
     Rooney & Associates
     Tél. : +1-212-223-4017
    mjanic@rooneyco.com     		Caroline Carmagnol
     Alize RP - Relation Presse
     Tél. : +33(0)6 64 18 99 59

    caroline@alizerp.com


    This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
    The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
    Source: DBV Technologies via Globenewswire

    Lesen Sie auch

    HUG#1935270
    Seite 3 von 3




    GlobeNewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Verfasst von GlobeNewswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    DBV Technologies IND Acceptance from FDA for a proof-of-concept trial using Viaskin® Milk in Milk-Induced Eosinophilic Esophagitis in Children - Seite 3  Press Release Bagneux, France, July 8, 2015 IND Acceptance from FDA for a proof-of-concept trial using Viaskin® Milk in Milk-Induced Eosinophilic Esophagitis in Children DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock …